Abstract Background Schisandrin B (Sch B), which inhibits hepatic steatosis caused by non-
alcoholic fatty liver disease (NAFLD), is one of the most active dibenzocyclooctadienes …

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease globally. The
progression of NAFLD is complex and associated with inflammation, oxidative stress …

Liver fibrosis is a major pathological feature of chronic liver diseases and there is no
effective therapy program at present. Schisandrin B (Sch B) is the major bioactive ingredient …

Nonalcoholic fatty liver disease (NAFLD) has become one of the most prominent causes of
chronic liver diseases and malignancies. However, few therapy has been approved. Radix …

Licochalcone A is a chalcone isolated from Glycyrrhiza uralensis. It showed anti-tumor and
anti-inflammatory properties in mice with acute lung injuries and regulated lipid metabolism …

Objective: Mangiferin (MGF) is a natural xanthone, with regulation effect on lipid metabolism.
However, the molecular mechanism remains unclear. We purposed after oral administration …

Objective Celastrol was recently identified as a potential novel treatment for obesity.
However, the effect of Celastrol on nonalcoholic fatty liver disease (NAFLD) remains elusive …

Non-alcoholic steatohepatitis (NASH) is a chronic metabolic syndrome and the CFLAR-JNK
pathway can reverse the process of NASH. Although silibinin is used for the treatment of …

Abstract Background and Aim Silybin is the major biologically active compound of silymarin,
the standardized extract of the milk thistle (Silybum marianum). Increasing numbers of …

Silybin shows good effects against obesity and metabolic syndrome, but the systemic
modulation effect of silybin has not been fully revealed. This study aims to investigate the …